{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:23:26Z","timestamp":1779186206177,"version":"3.51.4"},"reference-count":62,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"FPU grant from The Spanish Ministry of Education and Professional training","award":["FPU21\/00042"],"award-info":[{"award-number":["FPU21\/00042"]}]},{"name":"Gobierno de Navarra Proyecto ARNMUNE","award":["0011\u20131411-2023"],"award-info":[{"award-number":["0011\u20131411-2023"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP19\/00114"],"award-info":[{"award-number":["CP19\/00114"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI20\/00058"],"award-info":[{"award-number":["FI20\/00058"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00002"],"award-info":[{"award-number":["PI20\/00002"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00147"],"award-info":[{"award-number":["PI22\/00147"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007406","name":"BBVA Foundation","doi-asserted-by":"crossref","award":["2022 Leonardo Grant for Researchers and Cultural C"],"award-info":[{"award-number":["2022 Leonardo Grant for Researchers and Cultural C"]}],"id":[{"id":"10.13039\/100007406","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hookipa Pharma Inc","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Association against Cancer Research","award":["501100011033"],"award-info":[{"award-number":["501100011033"]}]},{"name":"Association against Cancer Research","award":["AECC-2019"],"award-info":[{"award-number":["AECC-2019"]}]},{"name":"Association against Cancer Research","award":["MCIN\/ AEI\/10.13039"],"award-info":[{"award-number":["MCIN\/ AEI\/10.13039"]}]},{"name":"Association against Cancer Research","award":["RYC2021-033381"],"award-info":[{"award-number":["RYC2021-033381"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,4,3]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Lymphocytic choriomeningitis virus (LCMV) belongs to the Arenavirus family known for inducing strong cytotoxic T-cell responses in both mice and humans. LCMV has been engineered for the development of cancer immunotherapies, currently undergoing evaluation in phase I\/II clinical trials. Initial findings have demonstrated safety and an exceptional ability to activate and expand tumor-specific T lymphocytes. Combination strategies to maximize the antitumor effectiveness of LCMV-based immunotherapies are being explored.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We assessed the antitumor therapeutic effects of intratumoral administration of polyinosinic:polycytidylic acid (poly(I:C)) and systemic vaccination using an LCMV-vector expressing non-oncogenic versions of the E6 and E7 antigens of human papillomavirus 16 (artLCMV-E7E6) in a bilateral model engrafting TC-1\/A9 cells. This cell line, derived from the parental TC-1, exhibits low MHC class I expression and is highly immune-resistant. The mechanisms underlying the combination\u2019s efficacy were investigated through bulk RNA-seq, flow cytometry analyses of the tumor microenvironment, selective depletions using antibodies and clodronate liposomes, Batf3 deficient mice, and in vivo bioluminescence experiments. Finally, we assessed the antitumor effectiveness of the combination of artLCMV-E7E6 with BO-112, a GMP-grade poly(I:C) formulated in polyethyleneimine, currently under evaluation in clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Intratumoral injection of poly(I:C) enhanced the antitumor efficacy of artLCMV-E7E6 in both injected and non-injected tumor lesions. The combined treatment resulted in a significant delay in tumor growth and often complete eradication of several tumor lesions, leading to significantly improved survival compared with monotherapies. While intratumoral administration of poly(I:C) did not impact LCMV vector biodistribution or transgene expression, it significantly modified leucocyte infiltrates within the tumor microenvironment and amplified systemic efficacy through proinflammatory cytokines\/chemokines such as CCL3, CCL5, CXCL10, TNF, IFN\u03b1, and IL12p70. Upregulation of MHC on tumor cells and a reconfiguration of the gene expression programs related to tumor vasculature, leucocyte migration, and the activation profile of tumor-infiltrating CD8<jats:sup>+<\/jats:sup> T lymphocytes were observed. Indeed, the antitumor effect relied on the functions of CD8<jats:sup>+<\/jats:sup> T lymphocytes and macrophages. The synergistic efficacy of the combination was further confirmed when BO-112 was included.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Intratumoral injection of poly(I:C) sensitizes MHC<jats:sup>low<\/jats:sup> tumors to the antitumor effects of artLCMV-E7E6, resulting in a potent therapeutic synergy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-008287","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:09:06Z","timestamp":1713312546000},"page":"e008287","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct05553639","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04630353","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04180215","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04180215","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04570332","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04508140","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04777708","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04420975","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05265650","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Celia","family":"Gomar","sequence":"first","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Augusta","family":"Di Trani","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Bella","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leire","family":"Arrizabalaga","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Gonzalez-Gomariz","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Fernandez-Sendin","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5969-9181","authenticated-orcid":false,"given":"Maite","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan Salvador","family":"Russo-Cabrera","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Ardaiz","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9364-474X","authenticated-orcid":false,"given":"Fernando","family":"Aranda","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Schippers","sequence":"additional","affiliation":[{"name":"Hookipa Pharma Inc, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisol","family":"Quintero","sequence":"additional","affiliation":[{"name":"Highlight Therapeutics, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Departments of Immunology and Oncology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus K","family":"Orlinger","sequence":"additional","affiliation":[{"name":"Hookipa Pharma Inc, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6062-5163","authenticated-orcid":false,"given":"Henning","family":"Lauterbach","sequence":"additional","affiliation":[{"name":"Hookipa Pharma Inc, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7410-1865","authenticated-orcid":false,"given":"Pedro","family":"Berraondo","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"2025100310011399000_12.4.e008287.1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1110522","article-title":"Arenaviruses: old viruses present new solutions for cancer therapy","volume":"14","author":"Stachura","year":"2023","journal-title":"Front Immunol"},{"key":"2025100310011399000_12.4.e008287.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2012.02.002"},{"key":"2025100310011399000_12.4.e008287.3","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.3390\/ijerph16224500","article-title":"Screening of forestry workers in Guadalajara province (Spain) for antibodies to lymphocytic Choriomeningitis virus, Hantavirus","volume":"16","author":"Lled\u00f3","year":"2019","journal-title":"IJERPH"},{"key":"2025100310011399000_12.4.e008287.4","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268805005431"},{"key":"2025100310011399000_12.4.e008287.5","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-010-8162-1"},{"key":"2025100310011399000_12.4.e008287.6","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.it.2015.09.005","article-title":"Tnfrs and control of chronic LCMV infection: implications for therapy","volume":"36","author":"Clouthier","year":"2015","journal-title":"Trends Immunol"},{"key":"2025100310011399000_12.4.e008287.7","doi-asserted-by":"publisher","DOI":"10.1038\/nature04444"},{"key":"2025100310011399000_12.4.e008287.8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.12.2205"},{"key":"2025100310011399000_12.4.e008287.9","doi-asserted-by":"publisher","DOI":"10.1038\/362758a0"},{"key":"2025100310011399000_12.4.e008287.10","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15327","article-title":"Replicating viral vector platform exploits Alarmin signals for potent CD8(+) T cell-mediated tumour immunotherapy","volume":"8","author":"Kallert","year":"2017","journal-title":"Nat Commun"},{"key":"2025100310011399000_12.4.e008287.11","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1809960","article-title":"Live-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancer","volume":"9","author":"Schmidt","year":"2020","journal-title":"Oncoimmunology"},{"key":"2025100310011399000_12.4.e008287.12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.732166","article-title":"Development and characterization of a novel non-lytic cancer Immunotherapy using a recombinant arenavirus vector platform","volume":"11","author":"Lauterbach","year":"2021","journal-title":"Front Oncol"},{"key":"2025100310011399000_12.4.e008287.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005276","article-title":"Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection","volume":"11","author":"Sommerstein","year":"2015","journal-title":"PLoS Pathog"},{"key":"2025100310011399000_12.4.e008287.14","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11061060","article-title":"Human papillomavirus epidemiology and prevention: is there still a gender gap?","volume":"11","author":"Milano","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"2025100310011399000_12.4.e008287.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810097"},{"key":"2025100310011399000_12.4.e008287.16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0321"},{"key":"2025100310011399000_12.4.e008287.17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26412"},{"key":"2025100310011399000_12.4.e008287.18","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/s41416-020-01239-z","article-title":"Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and alpha-PD-1","volume":"124","author":"Zalba","year":"2021","journal-title":"Br J Cancer"},{"key":"2025100310011399000_12.4.e008287.19","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1629259","article-title":"HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory","volume":"8","author":"Grunwitz","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025100310011399000_12.4.e008287.20","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.7314\/APJCP.2015.16.9.3843","article-title":"Immunotherapeutic effects of dendritic cells pulsed with a coden-optimized HPV 16 E6 and E7 fusion gene in vivo and in vitro","volume":"16","author":"Zhou","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"2025100310011399000_12.4.e008287.21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002953","article-title":"Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy","volume":"9","author":"Alvarez","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100310011399000_12.4.e008287.22","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2197370","article-title":"Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic","volume":"12","author":"Alvarez","year":"2023","journal-title":"Oncoimmunology"},{"key":"2025100310011399000_12.4.e008287.23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0391","article-title":"Intratumoral Nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors","volume":"12","author":"M\u00e1rquez-Rodas","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025100310011399000_12.4.e008287.24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005011","article-title":"Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control","volume":"11","author":"Rodriguez-Ruiz","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025100310011399000_12.4.e008287.25","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-5-10","article-title":"Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models","volume":"5","author":"Zhu","year":"2007","journal-title":"J Transl Med"},{"key":"2025100310011399000_12.4.e008287.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.09.009"},{"key":"2025100310011399000_12.4.e008287.27","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-CT014","article-title":"Abstract CT014: efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: final results of spotlight203 phase 2 study","volume":"82","author":"M\u00e1rquez-Rodas","year":"2022","journal-title":"Cancer Res"},{"key":"2025100310011399000_12.4.e008287.28","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164206"},{"key":"2025100310011399000_12.4.e008287.29","first-page":"2826","article-title":"Establishment and characterization of a mouse tumor cell line with irreversible downregulation of MHC class I molecules","volume":"42","author":"Lhotakova","year":"2019","journal-title":"Oncol Rep"},{"key":"2025100310011399000_12.4.e008287.30","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts635"},{"key":"2025100310011399000_12.4.e008287.31","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt656"},{"key":"2025100310011399000_12.4.e008287.32","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3252"},{"key":"2025100310011399000_12.4.e008287.33","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2004-5-10-r80","article-title":"Bioconductor: open software development for computational biology and bioinformatics","volume":"5","author":"Gentleman","year":"2004","journal-title":"Genome Biol"},{"key":"2025100310011399000_12.4.e008287.34","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp616"},{"key":"2025100310011399000_12.4.e008287.35","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118"},{"key":"2025100310011399000_12.4.e008287.36","unstructured":"Gomar C , Di CA , Bella A , et al . Data from: the efficacy of LCMV-based cancer vaccines is unleashed by intratumoral injections of polyI:C. NCBI\u2019s Gene Expression Omnibus; 2023. Available: https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE245436"},{"key":"2025100310011399000_12.4.e008287.37","doi-asserted-by":"crossref","unstructured":"Gomar C , Di CA , Bella A , et al . Data from: the efficacy of LCMV-based cancer vaccines is unleashed by Intratumoral injections of polyI:C [NCBI\u2019s Gene Expression Omnibus]. 2024. Available: https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE256478","DOI":"10.1136\/jitc-2023-008287"},{"key":"2025100310011399000_12.4.e008287.38","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/bloodadvances.2021005198","article-title":"FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology","volume":"6","author":"Botta","year":"2022","journal-title":"Blood Adv"},{"key":"2025100310011399000_12.4.e008287.39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41592-019-0654-x","article-title":"Orchestrating single-cell analysis with Bioconductor","volume":"17","author":"Amezquita","year":"2020","journal-title":"Nat Methods"},{"key":"2025100310011399000_12.4.e008287.40","doi-asserted-by":"publisher","DOI":"10.1021\/cb3002478"},{"key":"2025100310011399000_12.4.e008287.41","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat Cancer"},{"key":"2025100310011399000_12.4.e008287.42","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.111"},{"key":"2025100310011399000_12.4.e008287.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"2025100310011399000_12.4.e008287.44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/17460441.2021.1978972","article-title":"Advances in mRNA-based drug discovery in cancer immunotherapy","volume":"17","author":"Di Trani","year":"2022","journal-title":"Expert Opin Drug Discov"},{"key":"2025100310011399000_12.4.e008287.45","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd.2018.132","article-title":"An RNA toolbox for cancer immunotherapy","volume":"17","author":"Pastor","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2025100310011399000_12.4.e008287.46","doi-asserted-by":"publisher","DOI":"10.1038\/nature23003"},{"key":"2025100310011399000_12.4.e008287.47","doi-asserted-by":"publisher","DOI":"10.1038\/nature14426"},{"key":"2025100310011399000_12.4.e008287.48","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar7112"},{"key":"2025100310011399000_12.4.e008287.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y"},{"key":"2025100310011399000_12.4.e008287.50","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2B study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"2025100310011399000_12.4.e008287.51","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071760","article-title":"MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100310011399000_12.4.e008287.52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.844866","article-title":"Mechanisms of MHC-I downregulation and role in immunotherapy response","volume":"13","author":"Taylor","year":"2022","journal-title":"Front Immunol"},{"key":"2025100310011399000_12.4.e008287.53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"2025100310011399000_12.4.e008287.54","doi-asserted-by":"publisher","DOI":"10.1111\/J.1399-0039.1993.TB01981.X"},{"key":"2025100310011399000_12.4.e008287.55","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.346"},{"key":"2025100310011399000_12.4.e008287.56","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25333"},{"key":"2025100310011399000_12.4.e008287.57","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0328-y"},{"key":"2025100310011399000_12.4.e008287.58","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00507-y"},{"key":"2025100310011399000_12.4.e008287.59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1423356112"},{"key":"2025100310011399000_12.4.e008287.60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502582"},{"key":"2025100310011399000_12.4.e008287.61","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0510"},{"key":"2025100310011399000_12.4.e008287.62","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324341"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-008287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:01:29Z","timestamp":1759510889000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-008287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":62,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,16]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/jitc-2023-008287"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-008287","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}